文献速递心脑血管急症消化、代谢与肾脏急症

Ad26.COV2.S疫苗接种后血栓性血小板减少症及脑静脉窦血栓形成接受比伐芦定治疗的早期结局

Early Outcomes of Bivalirudin Therapy for Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After Ad26.COV2.S Vaccination.
PubMed 文献 · Ann Emerg Med · 2021-07-03
一句话结论单例Ad26.COV2.S疫苗接种后疑似疫苗诱导血栓性血小板减少症患者,用比伐芦定替代肝素后血小板上升、症状改善且无即刻不良结局。

本文报道一例40岁白人女性在接种Ad26.COV2.S新冠疫苗后出现血小板减少、脑静脉窦血栓形成和肺栓塞,疑似疫苗诱导血栓性血小板减少症。因CDC建议疑似该病患者使用肝素以外的替代抗凝,而当时尚无比伐芦定治疗该病的结局报道,作者用比伐芦定作为肝素替代进行治疗。患者血小板从住院第0天20×10^9/L升至出院第6天115×10^9/L、第9天门诊随访182×10^9/L,血红蛋白有一过性下降但无临床出血证据,无血栓临床后遗症状且头痛缓解。作者认为提供者可考虑比伐芦定作为疑似病例的肝素替代,但需更确切研究。

要点

  • 疑似Ad26.COV2.S疫苗接种后疫苗诱导血栓性血小板减少症者,CDC建议使用肝素以外的替代抗凝,但未具体推荐替代药物。
  • 本单例患者使用比伐芦定后血小板由住院第0天20×10^9/L升至出院第6天115×10^9/L、第9天门诊182×10^9/L。
  • 治疗期间血红蛋白一过性下降,但无临床出血证据,无血栓临床后遗症状,头痛缓解。
  • 原文提到Ad26.COV2.S接种后13天内与血栓性血小板减少症风险相关(小但显著)。
  • 比伐芦定作为肝素替代仅基于单例经验,作者明确需更确切研究后再定论。

适用人群与场景

  • 接种Ad26.COV2.S新冠疫苗后疑似疫苗诱导血栓性血小板减少症的患者;本文为40岁白人女性,表现为血小板减少、脑静脉窦血栓形成和肺栓塞。

诊断标准与关键阈值

  • 原文未提及具体的诊断标准名称、评分界值或启动/停止阈值;仅描述该患者有血小板减少、脑静脉窦血栓形成和肺栓塞。
  • 原文提及Ad26.COV2.S接种后13天内与血栓性血小板减少症风险相关。

处置流程与药物剂量

  • 对疑似疫苗诱导血栓性血小板减少症者,CDC建议使用肝素以外的替代抗凝(原文未列出具体替代药物)。
  • 本文单例使用比伐芦定作为肝素替代;原文未提及比伐芦定的剂量、单位、给药途径、频次或疗程,也未提及目标值。

红旗征与不能漏的情况

  • 接种Ad26.COV2.S后出现血小板减少、脑静脉窦血栓形成和肺栓塞,需考虑疫苗诱导血栓性血小板减少症并按CDC建议避免肝素、考虑替代抗凝。
  • 原文提及治疗中可出现血红蛋白一过性下降,需关注出血证据(该例无临床出血证据)。

研究设计与关键结果

  • 研究类型为单例病例报告(1例40岁白人女性),无对照组;干预为比伐芦定作为肝素替代。
  • 血小板计数:住院第0天20×10^9/L,出院第6天115×10^9/L,第9天门诊随访182×10^9/L。
  • 血红蛋白一过性下降但无临床出血证据;无血栓临床后遗症状,头痛缓解。

证据类型、等级与局限

  • 证据类型为单例病例报告;原文未给出证据等级或推荐强度。
  • 局限:仅1例、无对照、观察期短(随访至第9天),作者明确需更确切研究。

对床旁实践的改变

  • 对疑似Ad26.COV2.S疫苗接种后疫苗诱导血栓性血小板减少症者,可按CDC建议考虑肝素以外的替代抗凝;原文提示比伐芦定可作为待进一步研究前的考虑选项。
  • 原文未提供比伐芦定的具体剂量方案,不能据此形成通用推荐;适用与不适用人群原文未明确。
  • 常见陷阱:不能把单例经验外推为确切疗效结论;原文强调需更确切研究。

指南或共识出处

  • 美国疾病控制与预防中心(CDC)建议:疑似疫苗诱导血栓性血小板减少症者使用肝素以外的替代抗凝(原文未给出指南名称、年份或推荐等级)。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

Vaccine-induced thrombotic thrombocytopenia is a newly described disease process in the setting of expanding access to COVID-19 vaccination. The United States Centers for Disease Control and Prevention recommends treatment with an alternative to heparin in patients suspected of having vaccine-induced thrombotic thrombocytopenia. At this time there have been no reported outcomes from the treatment of vaccine-induced thrombotic thrombocytopenia with bivalirudin as a heparin alternative. We describe the early outcomes from the treatment of vaccine-induced thrombotic thrombocytopenia with bivalirudin as a heparin alternative. A 40-year-old Caucasian woman was found to have thrombocytopenia, cerebral venous sinus thrombosis, and pulmonary embolism following vaccination for COVID-19 with Ad26.COV2.S. She exhibited a steady rise in platelet count: 20×109/L at hospital day 0, 115×109/L at discharge on hospital day 6, and 182×109/L on outpatient follow-up on day 9. While the patient exhibited a transient drop in hemoglobin, there was no clinical evidence of bleeding. This patient did not demonstrate any clinical sequelae of thrombosis, and she reported resolution of her headache. Vaccination with Ad26.COV2.S appears to be associated with a small but significant risk for thrombotic thrombocytopenia within 13 days of receipt. The Centers for Disease Control and Prevention guidance to consider an alternative to heparin was not accompanied by specifically recommended alternatives. A single patient treated with bivalirudin for suspected vaccine-induced thrombotic thrombocytopenia subsequently experienced symptom improvement and a rise in platelet count and did not demonstrate any immediate negative outcomes. A provider may consider bivalirudin as an alternative to heparin in patients with suspected vaccine-induced thrombotic thrombocytopenia following Ad26.COV2.S vaccination, pending more definitive research.

来源:Ann Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Clark RT, Johnson L, Billotti J, et al. Early Outcomes of Bivalirudin Therapy for Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After Ad26.COV2.S Vaccination. Ann Emerg Med. 2021. PMID: 34226070. doi:10.1016/j.annemergmed.2021.04.035

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。